A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
NCT03174886
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Progressive Nonfluent Aphasia
Interventions
DRUG:
AADvac1 40 µg
DRUG:
AADvac1 160 µg
Sponsor
Axon Neuroscience SE